专利检索 cpc:"C07D215/60" 第 4 页

31.

发明授权
Di-nu-oxides of amino-substituted acridines and quinolines 失效
标题翻译：氨基取代的吖啶和喹啉的二氧化物

公开(公告)号：US2500131A

公开(公告)日：1950-03-07

申请号：US60193145

申请日：1945-06-27

申请人： RALPH L EVANS

发明人： FRED LINSKER

IPC分类号： C07D215/60 , C07D219/12

CPC分类号： C07D215/60 , C07D219/12

32.

发明授权
Preparation of 6-methoxyquinoline-nu-oxide 失效
标题翻译：制备6-甲氧基喹啉 - 氧化物

公开(公告)号：US2416658A

公开(公告)日：1947-02-25

申请号：US55948644

申请日：1944-10-19

申请人： LILLY CO ELI

发明人： ARENDONK ARTHUR M VAN

IPC分类号： C07D215/60

CPC分类号： C07D215/60

33.

发明申请
Metabolites of N-(4-{[6,7-Bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 审中-公开

公开(公告)号：US20190218182A1

公开(公告)日：2019-07-18

申请号：US16362863

申请日：2019-03-25

申请人： Exelixis, Inc.

发明人： Dana T. Aftab , Sriram Naganathan , Wei Xu , Steven Lacy , Linh Nguyen

IPC分类号： C07D215/22 , G01N33/487 , C07C233/60 , C07C305/24 , C07D215/60

CPC分类号： C07D215/22 , C07C233/60 , C07C305/24 , C07C2601/02 , C07D215/60 , G01N33/487 , G01N2570/00

摘要： The invention relates to metabolites of cabozantinib (I) as well as uses thereof.

34.

发明授权
Substituted quinoline compounds as S-nitrosoglutathione reductase inhibitors 有权

公开(公告)号：US09856219B2

公开(公告)日：2018-01-02

申请号：US15228088

申请日：2016-08-04

申请人： Nivalis Therapeutics, Inc.

发明人： Xicheng Sun , Jian Qiu , Adam Stout

IPC分类号： C07D215/20 , C07D215/46 , C07D215/00 , C07D215/42 , C07D215/54 , C07D215/60 , C07D401/04 , C07D401/10 , C07D409/04 , C07D409/14 , C07D413/10 , C07D417/10 , A61K31/47 , A61K31/4706 , A61K31/4709

CPC分类号： C07D215/20 , A61K31/47 , A61K31/4706 , A61K31/4709 , C07D215/00 , C07D215/42 , C07D215/46 , C07D215/54 , C07D215/60 , C07D401/04 , C07D401/10 , C07D409/04 , C07D409/14 , C07D413/10 , C07D417/10

摘要： The present invention is directed to novel quinoline compounds useful as S-nitrosoglutathione reductase (GSNOR) inhibitors, pharmaceutical compositions comprising such compounds, and methods of making and using the same.

35.

发明授权
Nitrocatechol derivatives as COMT inhibitors 有权
标题翻译：硝基邻苯二酚衍生物作为COMT抑制剂

公开(公告)号：US09550759B2

公开(公告)日：2017-01-24

申请号：US14541654

申请日：2014-11-14

申请人： BIAL—PORTELA & CA, S.A.

发明人： David Alexander Learmonth , Laszlo Erno Kiss , Pedro Nuno Leal Palma , Humberto Dos Santos Ferreira , Patricio Manuel Vieira Araujo Soares Da Silva

IPC分类号： A61K31/4412 , C07D413/14 , C07D213/89 , C07D215/60 , C07D271/06 , C07D271/107 , C07D401/04 , C07D405/04 , C07D413/04 , C07D413/06 , C07D413/12 , C07D417/04

CPC分类号： C07D413/14 , A61K31/4412 , C07D213/89 , C07D215/60 , C07D271/06 , C07D271/107 , C07D401/04 , C07D405/04 , C07D413/04 , C07D413/06 , C07D413/12 , C07D417/04

摘要： New compounds of formula I are described. The compounds have potentially valuable pharmaceutical properties in the treatment of some central and peripheral nervous system disorders.

摘要翻译： 描述了新的式I化合物。这些化合物在治疗一些中枢和周围神经系统疾病中具有潜在的有价值的药物性质。

36.

发明申请
Novel Substituted Bicyclic Aromatic Compounds as S-Nitrosoglutathione Reductase Inhibitors 审中-公开

公开(公告)号：US20160279117A1

公开(公告)日：2016-09-29

申请号：US15173926

申请日：2016-06-06

申请人： Nivalis Therapeutics, Inc.

发明人： Xicheng Sun , Jian Qiu , Adam Stout

IPC分类号： A61K31/47 , A61K31/517 , C12N9/99 , A61K31/53 , A61K31/472 , A61K31/4709 , A61K31/498

CPC分类号： A61K31/47 , A61K31/4709 , A61K31/472 , A61K31/498 , A61K31/517 , A61K31/53 , C07C65/105 , C07C65/17 , C07C65/24 , C07D213/79 , C07D215/06 , C07D215/20 , C07D215/60 , C07D217/04 , C07D217/16 , C07D237/24 , C07D239/26 , C07D239/28 , C07D239/34 , C07D239/74 , C07D241/24 , C07D241/42 , C07D249/18 , C07D253/10 , C07D257/04 , C07D295/155 , C07D401/04 , C07D401/10 , C07D403/10 , C07D405/04 , C07D409/04 , C07D409/14 , C07D413/10 , C07D417/10 , C12N9/0006 , C12N9/0065 , C12N9/99 , C12Y101/01284

摘要： The present invention is directed to novel substituted bicyclic aromatic compounds useful as S-nitrosoglutathione reductase (GSNOR) inhibitors, pharmaceutical compositions comprising such compounds, and methods of making and using the same.

37.

发明申请
SUBSTITUTED NAPHTHYRIDINE AND QUINOLINE COMPOUNDS AS MAO INHIBITORS 有权
标题翻译：取代的萘啶和喹啉化合物作为MAO抑制剂

公开(公告)号：US20160074377A1

公开(公告)日：2016-03-17

申请号：US14862874

申请日：2015-09-23

申请人： DART NEUROSCIENCE (CAYMAN) LTD.

发明人： Jillian Basinger , Graeme Freestone , Varsha Gupta , Alan Kaplan , Chi-Ching Mak , Benjamin Pratt , Vincent Santora , Dipanjan Sengupta , Lino Valdez

IPC分类号： A61K31/47 , A61K31/4375 , A61K31/4709

CPC分类号： A61K31/47 , A61K31/4375 , A61K31/4709 , C07D215/20 , C07D215/22 , C07D215/54 , C07D215/60 , C07D401/12 , C07D471/04

摘要： The invention provides a chemical entity of Formula (I) wherein R1, R2, R3, Y, and n have any of the values described herein and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies, detection and imaging techniques, and radioactive treatments; and therapies, including inhibiting MAO, and MAO-B selectively, enhancing neuronal plasticity, treating neurological disorders, providing neuroprotection, treating a cognitive impairment associated with a CNS disorder, enhancing the efficiency of cognitive and motor training, providing neurorecovery and neurorehabilitation, enhancing the efficiency of non-human animal training protocols, and treating treating peripheral disorders (including obesity, diabetes, and cardiometabolic disorders) and their associated co-morbidities.

摘要翻译： 本发明提供式（I）的化学实体，其中R 1，R 2，R 3，Y和n具有本文所述的任何值和包含这些化学实体的组合物; 制作方法; 并在广泛的方法中使用，包括代谢和反应动力学研究，检测和成像技术以及放射性治疗; 选择性地抑制MAO和MAO-B的治疗，增强神经元可塑性，治疗神经障碍，提供神经保护，治疗与CNS病症相关的认知障碍，提高认知和运动训练的效率，提供神经复发和神经康复，增强非人类动物训练方案的效率以及治疗外周疾病（包括肥胖，糖尿病和心脏代谢障碍）及其相关并发症的治疗。

38.

发明授权
Quinoline amide M1 receptor positive allosteric modulators 有权
标题翻译：喹啉酰胺M1受体阳性变构调节剂

公开(公告)号：US09199939B2

公开(公告)日：2015-12-01

申请号：US13515724

申请日：2010-12-13

申请人： Scott D. Kuduk , Kelly-Ann S. Schlegel , Zhi-Qiang Yang

发明人： Scott D. Kuduk , Kelly-Ann S. Schlegel , Zhi-Qiang Yang

IPC分类号： C07D401/06 , C07D215/48 , C07D215/60 , C07D409/14 , C07D413/06 , C07D405/12 , C07D401/14 , C07D413/14 , C07D405/14 , C07D417/14

CPC分类号： C07D215/60 , C07D215/48 , C07D401/04 , C07D401/06 , C07D401/10 , C07D401/14 , C07D405/12 , C07D405/14 , C07D409/14 , C07D413/06 , C07D413/10 , C07D413/14 , C07D417/10 , C07D417/14 , C07D471/04

摘要： The present invention is directed to quinoline amide compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

摘要翻译： 本发明涉及作为M1受体阳性变构调节剂的式（I）的喹啉酰胺化合物，其可用于治疗涉及M1受体的疾病，例如阿尔茨海默氏病，精神分裂症，疼痛或睡眠障碍。本发明还涉及包含该化合物的药物组合物，以及该化合物和组合物在治疗由M1受体介导的疾病中的用途。

39.

发明申请
NOVEL QUINOLONE DERIVATIVES 有权
标题翻译：新的喹诺酮衍生物

公开(公告)号：US20150299193A1

公开(公告)日：2015-10-22

申请号：US14652024

申请日：2013-12-23

申请人： CADILA HEALTHCARE LIMITED

发明人： Ranjit C. Desai , Vrajesh Pandya , Pankaj Ramanbhai Patel

IPC分类号： C07D471/04 , C07D409/04 , C07D401/12 , C07D215/58 , C07D417/12

CPC分类号： C07D471/04 , A61K31/4704 , C07D215/58 , C07D215/60 , C07D401/04 , C07D401/12 , C07D409/04 , C07D413/04 , C07D417/12 , C07D491/04 , C07D495/04 , C07D513/04

摘要： The present invention relates to novel compounds of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds in medicine and the intermediates involved in their preparation.

摘要翻译： 本发明涉及通式（I）的新化合物，其互变异构形式，其立体异构体，其药学上可接受的盐，含有它们的药物组合物，其制备方法，这些化合物在医药中的用途以及参与其制备的中间体。